First Time Loading...

Takara Bio Inc
TSE:4974

Watchlist Manager
Takara Bio Inc Logo
Takara Bio Inc
TSE:4974
Watchlist
Price: 1 086 JPY -1.18% Market Closed
Updated: May 18, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

121.3B
-1%
Assets
Growth Rates:
1 Year
-6%
3 Years
+35%
5 Years
+71%
7 Years
+81%
10 Years
+94%
9.7B
-10%
Liabilities
Growth Rates:
1 Year
-43%
3 Years
-37%
5 Years
+39%
7 Years
+34%
10 Years
+79%
111.5B
-0.7%
Equity
Growth Rates:
1 Year
-1%
3 Years
+50%
5 Years
+74%
7 Years
+86%
10 Years
+95%

Balance Sheet Decomposition
Takara Bio Inc

121.3B
Assets
9.7B
Liabilities
121.3B
Assets
9.7B
Liabilities
Current Assets 62.8B
Cash & Short-Term Investments 35.4B
Receivables 11.3B
Other Current Assets 16.1B
Non-Current Assets 58.5B
PP&E 49.1B
Intangibles 8B
Other Non-Current Assets 1.4B
Current Liabilities 7.2B
Accounts Payable 1.5B
Accrued Liabilities 962m
Other Current Liabilities 4.7B
Non-Current Liabilities 2.6B
Long-Term Debt 788m
Other Non-Current Liabilities 1.8B

Balance Sheet
Takara Bio Inc

Rotate your device to view
Balance Sheet
Currency: JPY
Mar-2015 Mar-2016 Mar-2017 Mar-2018 Mar-2019 Mar-2020 Mar-2021 Mar-2022 Mar-2023 Mar-2024
Assets
Cash & Cash Equivalents
20 584
19 384
28 078
17 537
17 033
18 266
25 993
23 633
51 847
35 416
Cash Equivalents
20 584
19 384
28 078
17 537
17 033
18 266
25 993
23 633
51 847
35 416
Short-Term Investments
3 299
9 721
2 000
2 000
2 000
2 000
0
0
0
0
Total Receivables
6 691
6 789
7 425
7 989
8 563
9 046
12 585
17 804
12 448
11 285
Accounts Receivables
6 691
6 789
7 425
7 989
8 563
9 046
12 585
17 338
12 204
11 252
Other Receivables
0
0
0
0
0
0
0
466
244
33
Inventory
4 637
5 099
5 461
6 010
6 735
7 593
9 183
24 065
11 087
11 850
Other Current Assets
1 236
1 165
1 000
980
944
1 482
1 354
2 639
2 187
4 208
Total Current Assets
36 447
42 158
43 964
34 516
35 275
38 387
49 115
68 141
77 569
62 759
PP&E Net
20 532
20 534
19 577
18 534
21 404
24 213
29 766
36 395
40 956
49 075
PP&E Gross
20 532
20 534
19 577
18 534
21 404
24 213
29 766
36 395
40 956
49 075
Accumulated Depreciation
13 955
13 598
13 517
15 600
13 783
14 325
14 329
15 886
18 600
22 129
Intangible Assets
1 157
1 054
1 088
5 904
5 030
4 349
3 224
2 850
2 373
1 539
Goodwill
1 840
1 641
1 213
8 259
7 598
7 006
6 149
6 309
6 674
6 488
Long-Term Investments
0
0
0
0
0
0
0
0
0
0
Other Long-Term Assets
1 451
1 204
1 301
1 457
1 733
1 054
1 496
2 017
1 630
1 391
Other Assets
1 840
1 641
1 213
8 259
7 598
7 006
6 149
6 309
6 674
6 488
Total Assets
66 425
N/A
66 591
+0%
67 143
+1%
68 670
+2%
71 040
+3%
75 009
+6%
89 750
+20%
115 712
+29%
129 202
+12%
121 252
-6%
Liabilities
Accounts Payable
1 939
1 690
1 944
1 875
1 536
1 027
2 077
1 959
2 323
1 543
Accrued Liabilities
191
196
425
333
593
557
739
923
1 065
962
Short-Term Debt
9
16
0
0
0
0
0
0
0
0
Current Portion of Long-Term Debt
0
48
47
0
0
134
138
137
151
180
Other Current Liabilities
3 251
3 480
3 609
3 537
3 888
4 530
10 237
14 361
10 836
4 483
Total Current Liabilities
5 439
5 430
6 025
5 745
6 017
6 248
13 191
17 380
14 375
7 168
Long-Term Debt
179
130
82
0
0
986
1 003
910
821
788
Deferred Income Tax
0
196
210
0
0
0
0
198
179
0
Minority Interest
101
102
100
106
85
95
120
191
235
279
Other Liabilities
726
725
841
966
928
1 184
1 254
1 160
1 373
1 512
Total Liabilities
6 884
N/A
6 583
-4%
7 258
+10%
6 817
-6%
7 030
+3%
8 513
+21%
15 568
+83%
19 839
+27%
16 983
-14%
9 747
-43%
Equity
Common Stock
14 965
14 965
14 965
14 965
14 965
14 965
14 965
14 965
14 965
14 965
Retained Earnings
8 142
9 295
10 432
12 285
15 401
18 501
27 085
45 009
57 047
53 471
Additional Paid In Capital
32 893
32 893
32 893
32 893
32 893
32 893
32 893
32 893
32 893
32 893
Other Equity
3 541
2 855
1 595
1 710
751
137
761
3 006
7 314
10 176
Total Equity
59 541
N/A
60 008
+1%
59 885
0%
61 853
+3%
64 010
+3%
66 496
+4%
74 182
+12%
95 873
+29%
112 219
+17%
111 505
-1%
Total Liabilities & Equity
66 425
N/A
66 591
+0%
67 143
+1%
68 670
+2%
71 040
+3%
75 009
+6%
89 750
+20%
115 712
+29%
129 202
+12%
121 252
-6%
Shares Outstanding
Common Shares Outstanding
120
120
120
120
120
120
120
120
120
120

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 138,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.